Ishita Drugs & Industries Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "72.44",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "72.44",
    "mcapval": "22.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE806D01016",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "38 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Ishita Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-ishita-drugs-3694511",
        "imagepath": "",
        "date": "2025-11-12 23:42:54",
        "description": "Answer:\nThe historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years.\n\nBreakdown:\nIshita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 20..."
      },
      {
        "title": "Are Ishita Drugs latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-latest-results-good-or-bad-3693150",
        "imagepath": "",
        "date": "2025-11-12 19:26:54",
        "description": "Ishita Drugs' latest financial results for Q2 FY26 indicate significant operational challenges. The company reported net sales of ₹3.07 crores, reflecting a sharp quarter-on-quarter decline of 43.15% from ₹5.40 crores in Q1 FY26. This substantial drop in revenue has translated into a corresponding decrease in profitability, with net profit falling to ₹0.14 crores, a decline of 53.33% from the previous quarter.\n\nThe operating margin also contracted, decreasing to 6.19%, down from 6.48% in Q1 FY26, while the PAT margin fell to 4.56%, a reduction of 100 basis points. These metrics suggest that the company is facing difficulties in maintaining consistent order flows and pricing power amid a competitive landscape in the pharmaceutical ingredients sector.\n\nDespite a year-on-year comparison showing only a 6.12% decline in net sales from ₹3.27 crores in Q2 FY25, the sequential performance highlights a concerning vo..."
      },
      {
        "title": "Ishita Drugs Faces Mixed Financial Trends Amidst Sales Growth and Liquidity Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ishita-drugs-industries-financial-trend-declines-from-flat-to-negative-amid-weak-performance-indicators-3692418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IshitaDrugsIndu_fintrenddot_3692418.png",
        "date": "2025-11-12 11:00:51",
        "description": "Ishita Drugs & Industries has reported a flat performance for the quarter ending September 2025, despite a notable 34.44% growth in net sales to Rs 8.47 crore. However, the company faces challenges with low operating cash flow and declining profit metrics, reflecting mixed performance in a competitive market."
      },
      {
        "title": "Ishita Drugs Q2 FY26: Sharp Sequential Decline Raises Concerns Despite YoY Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/ishita-drugs-q2-fy26-sharp-sequential-decline-raises-concerns-despite-yoy-growth-3692504",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IshitaDrugsIndu_quaterlyResult_3692504.png",
        "date": "2025-11-12 09:38:13",
        "description": "Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharma ingredients and drug intermediates, reported a concerning quarter-on-quarter decline in its Q2 FY26 results, with net profit falling 53.33% sequentially to ₹0.14 crores despite posting a modest year-on-year decline of 26.32%. The company's shares, trading at ₹72.49 with a market capitalisation of ₹22.00 crores, have declined 21.57% year-to-date, reflecting investor concerns about the company's operational momentum and competitive positioning in the pharmaceutical ingredients space."
      },
      {
        "title": "Why is Ishita Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ishita-drugs-fallingrising-3653564",
        "imagepath": "",
        "date": "2025-10-29 00:15:32",
        "description": "As of 28-Oct, Ishita Drugs & Industries Ltd is experiencing a decline in its stock price, currently at 72.10, which represents a decrease of 1.42 or 1.93%. The stock has underperformed its sector by 1.67% today and has been on a consecutive downward trend for the last two days, accumulating a total decline of 3.03%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past week, the stock has fallen by 2.91%, and its year-to-date performance shows a significant decline of 22.00%, contrasting sharply with the Sensex, which has gained 8.30% during the same period. Unfortunately, there is no information available regarding positive or negative factors that could further clarify the stock's recent movement.\n\nBroader Market Context: In comparison to the benchmark, Ishita Drugs has significantly underperformed, with a 1-mont..."
      },
      {
        "title": "How has been the historical performance of Ishita Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-ishita-drugs-3652809",
        "imagepath": "",
        "date": "2025-10-28 22:45:32",
        "description": "Answer:\nThe historical performance of Ishita Drugs shows a mixed trend in financial metrics over the years.\n\nBreakdown:\nIshita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but an increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, remaining at 15.00 Cr in March 2025 compared to 15.19 Cr in the previous year. The company's total expenditure (excluding depreciation) was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, leading to an operating profit of 1.00 Cr, which is an increase from 0.91 Cr in March 2024. Profit before tax also rose to 1.16 Cr in March 2025 from 0.99 Cr in March 2024, resulting in a profit after tax of 0.87 Cr, up from 0.75 Cr the previous year. The earnings per share improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 f..."
      },
      {
        "title": "Ishita Drugs Faces Evaluation Shift Amid Ongoing Performance Challenges and Financial Weaknesses",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-stock-rating-downgraded-to-strong-sell-amid-bearish-indicators-3650320",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IshitaDrugsIndu_mojoScore_3650320.png",
        "date": "2025-10-28 08:17:00",
        "description": "Ishita Drugs & Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a change in its evaluation, reflecting a more bearish technical outlook. Despite recent increases in net sales and profits, the company's long-term fundamentals reveal weaknesses, with performance lagging behind benchmark indices."
      },
      {
        "title": "Ishita Drugs & Industries Faces Mixed Technical Trends Amid Financial Performance Fluctuations",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-stock-rating-upgraded-from-strong-sell-to-sell-3637005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IshitaDrugsIndu_mojoScore_3637005.png",
        "date": "2025-10-21 08:21:06",
        "description": "Ishita Drugs & Industries has recently adjusted its evaluation score due to changes in technical trends. The stock has shown mixed performance, with a decline over the past year but a notable gain over three years. Financial results indicate growth, though long-term fundamentals present challenges."
      },
      {
        "title": "How has been the historical performance of Ishita Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-ishita-drugs-3636002",
        "imagepath": "",
        "date": "2025-10-20 22:39:42",
        "description": "Answer:\nThe historical performance of Ishita Drugs shows a mixed trend in various financial metrics over the years.\n\nBreakdown:\nIshita Drugs' net sales for the year ending March 2025 were reported at 15.00 crore, a slight decrease from 15.19 crore in March 2024, but an increase from 12.07 crore in March 2023. The total operating income mirrored this trend, with a total of 15.00 crore in March 2025 compared to 15.19 crore in the previous year. The company's total expenditure, excluding depreciation, decreased to 14.00 crore in March 2025 from 14.28 crore in March 2024. Consequently, the operating profit (PBDIT) rose to 1.34 crore in March 2025, up from 1.19 crore in March 2024. Profit before tax also increased to 1.16 crore in March 2025 from 0.99 crore in March 2024, leading to a profit after tax of 0.87 crore, compared to 0.75 crore in the previous year. The earnings per share (EPS) improved to 2.91 in Mar..."
      }
    ],
    "total": 101,
    "sid": "444125",
    "stock_news_url": "https://www.marketsmojo.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "04-Dec-2025",
      "details": "Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "02-Dec-2025",
      "details": "Disclosure under Regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "02-Dec-2025",
      "details": "Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticlas related party of Ishita Drugs and Industries Limited.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Ishita Drugs?

2025-11-12 23:42:54

Answer: The historical performance of Ishita Drugs shows a mixed trend in its financial metrics over the years. Breakdown: Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but a notable increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, reaching 15.00 Cr in March 2025. The company's total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax also rose to 1.16 Cr in March 2025, up from 0.99 Cr in March 2024, leading to a profit after tax of 0.87 Cr, compared to 0.75 Cr in the prior year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 from 10.81 Cr in March 20...

Are Ishita Drugs latest results good or bad?

2025-11-12 19:26:54

Ishita Drugs' latest financial results for Q2 FY26 indicate significant operational challenges. The company reported net sales of ₹3.07 crores, reflecting a sharp quarter-on-quarter decline of 43.15% from ₹5.40 crores in Q1 FY26. This substantial drop in revenue has translated into a corresponding decrease in profitability, with net profit falling to ₹0.14 crores, a decline of 53.33% from the previous quarter. The operating margin also contracted, decreasing to 6.19%, down from 6.48% in Q1 FY26, while the PAT margin fell to 4.56%, a reduction of 100 basis points. These metrics suggest that the company is facing difficulties in maintaining consistent order flows and pricing power amid a competitive landscape in the pharmaceutical ingredients sector. Despite a year-on-year comparison showing only a 6.12% decline in net sales from ₹3.27 crores in Q2 FY25, the sequential performance highlights a concerning vo...

Ishita Drugs Faces Mixed Financial Trends Amidst Sales Growth and Liquidity Challenges

2025-11-12 11:00:51

Ishita Drugs & Industries has reported a flat performance for the quarter ending September 2025, despite a notable 34.44% growth in net sales to Rs 8.47 crore. However, the company faces challenges with low operating cash flow and declining profit metrics, reflecting mixed performance in a competitive market.

Ishita Drugs Q2 FY26: Sharp Sequential Decline Raises Concerns Despite YoY Growth

2025-11-12 09:38:13

Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharma ingredients and drug intermediates, reported a concerning quarter-on-quarter decline in its Q2 FY26 results, with net profit falling 53.33% sequentially to ₹0.14 crores despite posting a modest year-on-year decline of 26.32%. The company's shares, trading at ₹72.49 with a market capitalisation of ₹22.00 crores, have declined 21.57% year-to-date, reflecting investor concerns about the company's operational momentum and competitive positioning in the pharmaceutical ingredients space.

Why is Ishita Drugs falling/rising?

2025-10-29 00:15:32

As of 28-Oct, Ishita Drugs & Industries Ltd is experiencing a decline in its stock price, currently at 72.10, which represents a decrease of 1.42 or 1.93%. The stock has underperformed its sector by 1.67% today and has been on a consecutive downward trend for the last two days, accumulating a total decline of 3.03%. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past week, the stock has fallen by 2.91%, and its year-to-date performance shows a significant decline of 22.00%, contrasting sharply with the Sensex, which has gained 8.30% during the same period. Unfortunately, there is no information available regarding positive or negative factors that could further clarify the stock's recent movement. Broader Market Context: In comparison to the benchmark, Ishita Drugs has significantly underperformed, with a 1-mont...

How has been the historical performance of Ishita Drugs?

2025-10-28 22:45:32

Answer: The historical performance of Ishita Drugs shows a mixed trend in financial metrics over the years. Breakdown: Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but an increase from 12.07 Cr in March 2023. The total operating income mirrored this trend, remaining at 15.00 Cr in March 2025 compared to 15.19 Cr in the previous year. The company's total expenditure (excluding depreciation) was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, leading to an operating profit of 1.00 Cr, which is an increase from 0.91 Cr in March 2024. Profit before tax also rose to 1.16 Cr in March 2025 from 0.99 Cr in March 2024, resulting in a profit after tax of 0.87 Cr, up from 0.75 Cr the previous year. The earnings per share improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets increased to 16.30 Cr in March 2025 f...

Ishita Drugs Faces Evaluation Shift Amid Ongoing Performance Challenges and Financial Weaknesses

2025-10-28 08:17:00

Ishita Drugs & Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a change in its evaluation, reflecting a more bearish technical outlook. Despite recent increases in net sales and profits, the company's long-term fundamentals reveal weaknesses, with performance lagging behind benchmark indices.

Ishita Drugs & Industries Faces Mixed Technical Trends Amid Financial Performance Fluctuations

2025-10-21 08:21:06

Ishita Drugs & Industries has recently adjusted its evaluation score due to changes in technical trends. The stock has shown mixed performance, with a decline over the past year but a notable gain over three years. Financial results indicate growth, though long-term fundamentals present challenges.

How has been the historical performance of Ishita Drugs?

2025-10-20 22:39:42

Answer: The historical performance of Ishita Drugs shows a mixed trend in various financial metrics over the years. Breakdown: Ishita Drugs' net sales for the year ending March 2025 were reported at 15.00 crore, a slight decrease from 15.19 crore in March 2024, but an increase from 12.07 crore in March 2023. The total operating income mirrored this trend, with a total of 15.00 crore in March 2025 compared to 15.19 crore in the previous year. The company's total expenditure, excluding depreciation, decreased to 14.00 crore in March 2025 from 14.28 crore in March 2024. Consequently, the operating profit (PBDIT) rose to 1.34 crore in March 2025, up from 1.19 crore in March 2024. Profit before tax also increased to 1.16 crore in March 2025 from 0.99 crore in March 2024, leading to a profit after tax of 0.87 crore, compared to 0.75 crore in the previous year. The earnings per share (EPS) improved to 2.91 in Mar...

View All News